Evolution of tuberculosis in Spain: Will the objectives of the End TB Strategy be achieved in Western European countries?
End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countri...
Uložené v:
| Vydané v: | Enfermedades infecciosas y microbiologia clinica (English ed.) Ročník 43; číslo 7; s. 426 - 434 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Spain
Elsevier España, S.L.U
01.08.2025
|
| Predmet: | |
| ISSN: | 2529-993X, 2529-993X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countries (WEC).
Retrospective longitudinal ecological study with forecasting.
An exponential curve was fitted to the Spanish and WEC data prior the pandemic period and projected with the model until 2025 using a 90% confidence interval to have better precision due to the sample size.
The mean annual % change in incidence rates of TB in the three most affected WEC during 2018–2022 decreased by 6.5% in Spain, by 6.0% in Portugal, by 3.8% in Belgium and by 5.7% in France. The annual decrease in Spain in the first year of COVID-19 pandemic was 16.6%. Lower declines than in Spain were observed in most WEC. The probability of achieving the objective of reducing the incidence by 50% between 2015 and 2025 in Spain is, with a certainty of 90%, 0%, but with important differences by regions from 0% to 79%. These probabilities in Portugal, Belgium, France and Italy are also 0%.
With this epidemiological evolution, the main objective of the End TB Strategy for 2025 milestone (50% incidence decline) will not be achieved in Spain. The 80% decline will probably not be reached by 2030 unless surveillance and control are improved, and TB Programmes are provided with sufficient resources. The same situation could be happening in other WEC.
La Estrategia fin de la TB tiene como objetivo reducir la incidencia de la tuberculosis entre 2015 y 2025 en un 50%. Analizamos si los objetivos de disminución de la incidencia de esta estrategia pueden lograrse en España con el impacto de la pandemia de COVID-19 y revisamos su evolución en los países de Europa occidental (PEO).
Estudio ecológico longitudinal retrospectivo con pronóstico.
Se ajustó una curva exponencial a los datos de España y de los PEO antes del período pandémico y se proyectó con el modelo hasta 2025 utilizando un intervalo de confianza del 90% para tener una mejor precisión debido al tamaño de la muestra.
El cambio porcentual medio anual en las tasas de incidencia de TB en los 3 PEO más afectados durante 2018-2022 disminuyó en un 6,5% en España, en un 6,0% en Portugal, en un 3,8% en Bélgica y en un 5,7% en Francia. La disminución anual en España en el primer año de la pandemia de COVID-19 fue del 16,6%. Se observaron descensos menores que en España en la mayoría de los PEO. La probabilidad de alcanzar el objetivo de reducir la incidencia en un 50% entre 2015-2025 en España es, con una certeza del 90%, del 0%, pero con importantes diferencias entre regiones, desde el 0% hasta el 79%. Estas probabilidades en Portugal, Bélgica, Francia e Italia también son del 0%.
Con esta evolución epidemiológica el objetivo principal de la Estrategia fin de la TB para el hito de 2025 (reducción del 50% en la incidencia) no se logrará en España. La disminución del 80% probablemente no se alcanzará para 2030, a menos que se mejoren la vigilancia y el control y se proporcionen suficientes recursos a los programas de TB. La misma situación podría estar ocurriendo en otros PEO. |
|---|---|
| AbstractList | End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countries (WEC).OBJECTIVESEnd TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countries (WEC).Retrospective longitudinal ecological study with forecasting.STUDY DESIGNRetrospective longitudinal ecological study with forecasting.An exponential curve was fitted to the Spanish and WEC data prior the pandemic period and projected with the model until 2025 using a 90% confidence interval to have better precision due to the sample size.METHODOLOGYAn exponential curve was fitted to the Spanish and WEC data prior the pandemic period and projected with the model until 2025 using a 90% confidence interval to have better precision due to the sample size.The mean annual % change in incidence rates of TB in the three most affected WEC during 2018-2022 decreased by 6.5% in Spain, by 6.0% in Portugal, by 3.8% in Belgium and by 5.7% in France. The annual decrease in Spain in the first year of COVID-19 pandemic was 16.6%. Lower declines than in Spain were observed in most WEC. The probability of achieving the objective of reducing the incidence by 50% between 2015 and 2025 in Spain is, with a certainty of 90%, 0%, but with important differences by regions from 0% to 79%. These probabilities in Portugal, Belgium, France and Italy are also 0%.RESULTSThe mean annual % change in incidence rates of TB in the three most affected WEC during 2018-2022 decreased by 6.5% in Spain, by 6.0% in Portugal, by 3.8% in Belgium and by 5.7% in France. The annual decrease in Spain in the first year of COVID-19 pandemic was 16.6%. Lower declines than in Spain were observed in most WEC. The probability of achieving the objective of reducing the incidence by 50% between 2015 and 2025 in Spain is, with a certainty of 90%, 0%, but with important differences by regions from 0% to 79%. These probabilities in Portugal, Belgium, France and Italy are also 0%.With this epidemiological evolution, the main objective of the End TB Strategy for 2025 milestone (50% incidence decline) will not be achieved in Spain. The 80% decline will probably not be reached by 2030 unless surveillance and control are improved, and TB Programmes are provided with sufficient resources. The same situation could be happening in other WEC.CONCLUSIONWith this epidemiological evolution, the main objective of the End TB Strategy for 2025 milestone (50% incidence decline) will not be achieved in Spain. The 80% decline will probably not be reached by 2030 unless surveillance and control are improved, and TB Programmes are provided with sufficient resources. The same situation could be happening in other WEC. End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countries (WEC). Retrospective longitudinal ecological study with forecasting. An exponential curve was fitted to the Spanish and WEC data prior the pandemic period and projected with the model until 2025 using a 90% confidence interval to have better precision due to the sample size. The mean annual % change in incidence rates of TB in the three most affected WEC during 2018-2022 decreased by 6.5% in Spain, by 6.0% in Portugal, by 3.8% in Belgium and by 5.7% in France. The annual decrease in Spain in the first year of COVID-19 pandemic was 16.6%. Lower declines than in Spain were observed in most WEC. The probability of achieving the objective of reducing the incidence by 50% between 2015 and 2025 in Spain is, with a certainty of 90%, 0%, but with important differences by regions from 0% to 79%. These probabilities in Portugal, Belgium, France and Italy are also 0%. With this epidemiological evolution, the main objective of the End TB Strategy for 2025 milestone (50% incidence decline) will not be achieved in Spain. The 80% decline will probably not be reached by 2030 unless surveillance and control are improved, and TB Programmes are provided with sufficient resources. The same situation could be happening in other WEC. End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countries (WEC). Retrospective longitudinal ecological study with forecasting. An exponential curve was fitted to the Spanish and WEC data prior the pandemic period and projected with the model until 2025 using a 90% confidence interval to have better precision due to the sample size. The mean annual % change in incidence rates of TB in the three most affected WEC during 2018–2022 decreased by 6.5% in Spain, by 6.0% in Portugal, by 3.8% in Belgium and by 5.7% in France. The annual decrease in Spain in the first year of COVID-19 pandemic was 16.6%. Lower declines than in Spain were observed in most WEC. The probability of achieving the objective of reducing the incidence by 50% between 2015 and 2025 in Spain is, with a certainty of 90%, 0%, but with important differences by regions from 0% to 79%. These probabilities in Portugal, Belgium, France and Italy are also 0%. With this epidemiological evolution, the main objective of the End TB Strategy for 2025 milestone (50% incidence decline) will not be achieved in Spain. The 80% decline will probably not be reached by 2030 unless surveillance and control are improved, and TB Programmes are provided with sufficient resources. The same situation could be happening in other WEC. La Estrategia fin de la TB tiene como objetivo reducir la incidencia de la tuberculosis entre 2015 y 2025 en un 50%. Analizamos si los objetivos de disminución de la incidencia de esta estrategia pueden lograrse en España con el impacto de la pandemia de COVID-19 y revisamos su evolución en los países de Europa occidental (PEO). Estudio ecológico longitudinal retrospectivo con pronóstico. Se ajustó una curva exponencial a los datos de España y de los PEO antes del período pandémico y se proyectó con el modelo hasta 2025 utilizando un intervalo de confianza del 90% para tener una mejor precisión debido al tamaño de la muestra. El cambio porcentual medio anual en las tasas de incidencia de TB en los 3 PEO más afectados durante 2018-2022 disminuyó en un 6,5% en España, en un 6,0% en Portugal, en un 3,8% en Bélgica y en un 5,7% en Francia. La disminución anual en España en el primer año de la pandemia de COVID-19 fue del 16,6%. Se observaron descensos menores que en España en la mayoría de los PEO. La probabilidad de alcanzar el objetivo de reducir la incidencia en un 50% entre 2015-2025 en España es, con una certeza del 90%, del 0%, pero con importantes diferencias entre regiones, desde el 0% hasta el 79%. Estas probabilidades en Portugal, Bélgica, Francia e Italia también son del 0%. Con esta evolución epidemiológica el objetivo principal de la Estrategia fin de la TB para el hito de 2025 (reducción del 50% en la incidencia) no se logrará en España. La disminución del 80% probablemente no se alcanzará para 2030, a menos que se mejoren la vigilancia y el control y se proporcionen suficientes recursos a los programas de TB. La misma situación podría estar ocurriendo en otros PEO. |
| Author | Pérez Jiménez, Pilar Gavaldà, Laura Montaño Remacha, Mª Carmen Giménez Durán, Jaume Vázquez Rincón, Isabel López, Mar Guirado Esteban, Isidro Durán Pla, Enric Tabernero, Eva M. Rodrigo, Teresa Rodríguez Baena, Mª Elena Fernández Ibáñez, Ana Millet, Joan P. Caylà, Joan A. Cruz Ferro, Elena Castrillejo Pérez, Daniel Bravo, Mario Pequeño, Sandra Castilla Catalán, Jesús |
| Author_xml | – sequence: 1 givenname: Teresa surname: Rodrigo fullname: Rodrigo, Teresa email: pii_tb_teresa_rodrigo@separ.es organization: Programa Integrado de Investigación en Tuberculosis y Micobacterias no Tuberculosas (PII-TB&MNT) de SEPAR, Barcelona, Spain – sequence: 2 givenname: Joan P. surname: Millet fullname: Millet, Joan P. organization: Programa Integrado de Investigación en Tuberculosis y Micobacterias no Tuberculosas (PII-TB&MNT) de SEPAR, Barcelona, Spain – sequence: 3 givenname: Mario surname: Bravo fullname: Bravo, Mario organization: Serveis Clínics de Barcelona, Spain – sequence: 4 givenname: Eva M. surname: Tabernero fullname: Tabernero, Eva M. organization: Programa Integrado de Investigación en Tuberculosis y Micobacterias no Tuberculosas (PII-TB&MNT) de SEPAR, Barcelona, Spain – sequence: 5 givenname: Joan A. surname: Caylà fullname: Caylà, Joan A. organization: Barcelona Tuberculosis Research Unit Foundation (fuiTB), Barcelona, Spain – sequence: 6 givenname: Isabel surname: Vázquez Rincón fullname: Vázquez Rincón, Isabel organization: CA Andalucía – sequence: 7 givenname: Enric surname: Durán Pla fullname: Durán Pla, Enric organization: CA Andalucía – sequence: 8 givenname: Mª Carmen surname: Montaño Remacha fullname: Montaño Remacha, Mª Carmen organization: CA Aragón – sequence: 9 givenname: Ana surname: Fernández Ibáñez fullname: Fernández Ibáñez, Ana organization: CA Asturias – sequence: 10 givenname: Jaume surname: Giménez Durán fullname: Giménez Durán, Jaume organization: CA Islas Baleares – sequence: 11 givenname: Pilar surname: Pérez Jiménez fullname: Pérez Jiménez, Pilar organization: CA Castilla-La Mancha – sequence: 12 givenname: Sandra surname: Pequeño fullname: Pequeño, Sandra organization: CA Cataluña – sequence: 13 givenname: Mar surname: López fullname: López, Mar organization: CA Cataluña – sequence: 14 givenname: Laura surname: Gavaldà fullname: Gavaldà, Laura organization: CA Cataluña – sequence: 15 givenname: Elena surname: Cruz Ferro fullname: Cruz Ferro, Elena organization: CA Galicia – sequence: 16 givenname: Mª Elena surname: Rodríguez Baena fullname: Rodríguez Baena, Mª Elena organization: CA Madrid – sequence: 17 givenname: Isidro surname: Guirado Esteban fullname: Guirado Esteban, Isidro organization: CA Murcia – sequence: 18 givenname: Jesús surname: Castilla Catalán fullname: Castilla Catalán, Jesús organization: CA Navarra – sequence: 19 givenname: Daniel surname: Castrillejo Pérez fullname: Castrillejo Pérez, Daniel organization: Ciudad Autónoma Melilla |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40467409$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1LXDEUxUOxVKv-BYWSZTfzmq_3xhRKaWW0gtCFit2FfNzUDG-SaZI3MP99M45CceEql_A7h3vPeY8OYoqA0AdKOkro8HnZQVhZ6BhhfUdYR-j8DTpiPZMzKfnvg__mQ3RaypIQwuRAey7eoUNBxDAXRB6h7WKTxqmGFHHyuE4Gsp3GVELBIeKbtQ7xC74P44jrA-BklmBr2EB5pNvPIjp8-wPf1Kwr_NliA1jbhwAbcDuDeygVcsSLKac16IhtmmLNAcq3E_TW67HA6dN7jO4uFrfnP2fXvy6vzr9fzywjQs54LzVj2riBWA8eeuYNpYMxAFxQwsWcSjFnwlPjDNdn3rAWECHOatu7wfNj9Gnvu87p79T2UatQLIyjjpCmojijvTzrCeMN_fiETmYFTq1zWOm8Vc9xNUDuAZtTKRm8sqHqXXrt_jAqStSuHbVUj-2oXTuKMNXaaVr-Qvts_7rq614FLaJNgKyKDRAtuJBbFcql8Kr-H6zuqnA |
| CitedBy_id | crossref_primary_10_3390_antibiotics14090875 |
| Cites_doi | 10.1007/s00586-012-2334-8 10.1016/S0140-6736(10)60483-7 10.1016/S1473-3099(24)00007-0 10.3201/eid2703.203456 10.1016/j.arbres.2023.09.002 10.1016/S0213-005X(11)70011-8 10.1016/S0025-7753(00)71354-6 10.3201/eid2611.203163 10.1001/jama.1995.03520270054031 |
| ContentType | Journal Article |
| Contributor | Pérez Jiménez, Pilar Gavaldà, Laura Montaño Remacha, Mª Carmen Giménez Durán, Jaume Vázquez Rincón, Isabel López, Mar Guirado Esteban, Isidro Durán Pla, Enric Rodríguez Baena, Mª Elena Fernández Ibáñez, Ana Cruz Ferro, Elena Castrillejo Pérez, Daniel Pequeño, Sandra Castilla Catalán, Jesús |
| Contributor_xml | – sequence: 1 givenname: Isabel surname: Vázquez Rincón fullname: Vázquez Rincón, Isabel organization: CA Andalucía – sequence: 2 givenname: Enric surname: Durán Pla fullname: Durán Pla, Enric organization: CA Andalucía – sequence: 3 givenname: Mª Carmen surname: Montaño Remacha fullname: Montaño Remacha, Mª Carmen organization: CA Aragón – sequence: 4 givenname: Ana surname: Fernández Ibáñez fullname: Fernández Ibáñez, Ana organization: CA Asturias – sequence: 5 givenname: Jaume surname: Giménez Durán fullname: Giménez Durán, Jaume organization: CA Islas Baleares – sequence: 6 givenname: Pilar surname: Pérez Jiménez fullname: Pérez Jiménez, Pilar organization: CA Castilla-La Mancha – sequence: 7 givenname: Sandra surname: Pequeño fullname: Pequeño, Sandra organization: CA Cataluña – sequence: 8 givenname: Mar surname: López fullname: López, Mar organization: CA Cataluña – sequence: 9 givenname: Laura surname: Gavaldà fullname: Gavaldà, Laura organization: CA Cataluña – sequence: 10 givenname: Elena surname: Cruz Ferro fullname: Cruz Ferro, Elena organization: CA Galicia – sequence: 11 givenname: Mª Elena surname: Rodríguez Baena fullname: Rodríguez Baena, Mª Elena organization: CA Madrid – sequence: 12 givenname: Isidro surname: Guirado Esteban fullname: Guirado Esteban, Isidro organization: CA Murcia – sequence: 13 givenname: Jesús surname: Castilla Catalán fullname: Castilla Catalán, Jesús organization: CA Navarra – sequence: 14 givenname: Daniel surname: Castrillejo Pérez fullname: Castrillejo Pérez, Daniel organization: Ciudad Autónoma Melilla |
| Copyright | 2025 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica Copyright © 2025 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved. |
| Copyright_xml | – notice: 2025 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica – notice: Copyright © 2025 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved. |
| CorporateAuthor | Tuberculosis Prevention and Control Programmes of the Autonomous Communities Working Group |
| CorporateAuthor_xml | – name: Tuberculosis Prevention and Control Programmes of the Autonomous Communities Working Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.eimce.2025.02.017 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Evolución de la tuberculosis en España: ¿se lograrán los objetivos de la Estrategia fin de la TB en los países de Europa occidental? |
| EISSN | 2529-993X |
| EndPage | 434 |
| ExternalDocumentID | 40467409 10_1016_j_eimce_2025_02_017 S2529993X25001364 |
| Genre | Journal Article |
| GeographicLocations | Europe Spain |
| GeographicLocations_xml | – name: Spain – name: Europe |
| GroupedDBID | --M 0R~ AAEDT AAEDW AAKOC AALRI AAOAW AAQFI AATTM AAXUO AAYWO ABJNI ABMAC ACDAQ ACGFS ACRLP ACVFH ADBBV ADCNI AEBSH AEIPS AEUPX AFJKZ AFPUW AFTJW AFXIZ AGCQF AGUBO AIEXJ AIGII AIIUN AIKHN AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU AXJTR BNPGV CJTIS EBS EFJIC EFKBS EJD FDB FIRID KOM M41 O9- ROL SPCBC SSH SSI SSZ T5K ~G- AAYXX ACLOT CITATION EFLBG AGRNS CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c2049-359a22abd60cfefe52fb116bbee3410347194724f1bdb3a8fb210100dcac5d6f3 |
| ISSN | 2529-993X |
| IngestDate | Thu Oct 02 22:37:32 EDT 2025 Tue Aug 05 01:30:30 EDT 2025 Tue Nov 18 22:29:23 EST 2025 Sat Nov 29 07:44:19 EST 2025 Sat Aug 23 17:11:10 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | COVID-19 Programas de control Evaluation Control programmes Elimination Eliminación Incidencia Incidence Evaluación |
| Language | English |
| License | Copyright © 2025 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c2049-359a22abd60cfefe52fb116bbee3410347194724f1bdb3a8fb210100dcac5d6f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 40467409 |
| PQID | 3215985023 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_3215985023 pubmed_primary_40467409 crossref_citationtrail_10_1016_j_eimce_2025_02_017 crossref_primary_10_1016_j_eimce_2025_02_017 elsevier_sciencedirect_doi_10_1016_j_eimce_2025_02_017 |
| PublicationCentury | 2000 |
| PublicationDate | 2025 Aug-Sep |
| PublicationDateYYYYMMDD | 2025-08-01 |
| PublicationDate_xml | – month: 08 year: 2025 text: 2025 Aug-Sep |
| PublicationDecade | 2020 |
| PublicationPlace | Spain |
| PublicationPlace_xml | – name: Spain |
| PublicationTitle | Enfermedades infecciosas y microbiologia clinica (English ed.) |
| PublicationTitleAlternate | Enferm Infecc Microbiol Clin (Engl Ed) |
| PublicationYear | 2025 |
| Publisher | Elsevier España, S.L.U |
| Publisher_xml | – name: Elsevier España, S.L.U |
| References | Orcau, Caylà, Martínez (bib0275) 2011; 29 (bib0155) 2023 [accessed Nov 2024] (bib0235) 2024; 24 European Centre for Disease Prevention and Control, WHO Regional Office for Europe (bib0215) 2024 [accessed Nov 2024] [revised April 2024]. (bib0165) 2015 [accessed Nov 2024] Rodrigo, Caylà, Galdós-Tangüis, Jansá, Brugal, García de Olalla (bib0225) 1999 [accessed Nov 2024]; 113 (bib0200) 2020 [accessed Nov 2024] (bib0260) 2023 [accessed Nov 2024] Centis, D’Ambrosio, Kurhasani, Solovic, Migliori (bib0230) 2023; 59 (bib0280) 2024 [accessed Nov 2024] (bib0185) 2007 [accessed Nov 2024] (bib0220) 2023 [accessed Nov 2024] (bib0270) 2024 [accessed Nov 2024] (bib0170) 2016 [accessed Nov 2024] Díez (bib0175) 1997; 1 (bib0240) 2022 [accessed Nov 2024] [revised March 2024]. Red Nacional de Vigilancia Epidemiológica (RENAVE). Informe epidemiológico sobre la situación de la tuberculosis en España. Años del 2015 al 2021. Centro Nacional de Epidemiología. Instituto de Salud Carlos III [Internet] [accessed Nov 2024]. Available from (bib0190) 2019 [accessed Nov 2024] Lönnroth, Castro, Muhwa Chakaya, Singh Chauhan, Floyd, Glaziou (bib0265) 2010; 375 Hopewell, Reichman, Gastro (bib0195) 2021; 27 Raviglione, Snider, Kochi (bib0150) 1995; 273 (bib0255) 2021 [accessed Nov 2024] Millet, Moreno, Fina, Del Baño, Orcau, García de Olalla (bib0245) 2013; 22 Red Nacional de Vigilancia Epidemiológica (RENAVE). Informe epidemiológico sobre la situación de la tuberculosis en España. Año 2022. Centro Nacional de Epidemiología. Instituto de Salud Carlos III [Internet] [accessed Nov 2024]. Available from (bib0145) 1994 [accessed Nov 2024] Migliori, Tanga, Akkerman, Alffenaar, Álvarez-Navascués, Assao-Neino (bib0205) 2020; 26 (bib0180) 2000; 114 Sudre, ten Dam, Kochi (bib0160) 1992; 70 (10.1016/j.eimce.2025.02.017_bib0145) 1994 10.1016/j.eimce.2025.02.017_bib0210 Sudre (10.1016/j.eimce.2025.02.017_bib0160) 1992; 70 (10.1016/j.eimce.2025.02.017_bib0185) 2007 (10.1016/j.eimce.2025.02.017_bib0180) 2000; 114 Migliori (10.1016/j.eimce.2025.02.017_bib0205) 2020; 26 Centis (10.1016/j.eimce.2025.02.017_bib0230) 2023; 59 European Centre for Disease Prevention and Control (10.1016/j.eimce.2025.02.017_bib0215) 2024 (10.1016/j.eimce.2025.02.017_bib0190) 2019 Raviglione (10.1016/j.eimce.2025.02.017_bib0150) 1995; 273 (10.1016/j.eimce.2025.02.017_bib0170) 2016 Lönnroth (10.1016/j.eimce.2025.02.017_bib0265) 2010; 375 10.1016/j.eimce.2025.02.017_bib0250 (10.1016/j.eimce.2025.02.017_bib0235) 2024; 24 Millet (10.1016/j.eimce.2025.02.017_bib0245) 2013; 22 (10.1016/j.eimce.2025.02.017_bib0165) 2015 (10.1016/j.eimce.2025.02.017_bib0280) 2024 Orcau (10.1016/j.eimce.2025.02.017_bib0275) 2011; 29 (10.1016/j.eimce.2025.02.017_bib0270) 2024 Hopewell (10.1016/j.eimce.2025.02.017_bib0195) 2021; 27 (10.1016/j.eimce.2025.02.017_bib0255) 2021 Díez (10.1016/j.eimce.2025.02.017_bib0175) 1997; 1 (10.1016/j.eimce.2025.02.017_bib0220) 2023 (10.1016/j.eimce.2025.02.017_bib0260) 2023 (10.1016/j.eimce.2025.02.017_bib0155) 2023 (10.1016/j.eimce.2025.02.017_bib0240) 2022 Rodrigo (10.1016/j.eimce.2025.02.017_bib0225) 1999; 113 (10.1016/j.eimce.2025.02.017_bib0200) 2020 |
| References_xml | – reference: Red Nacional de Vigilancia Epidemiológica (RENAVE). Informe epidemiológico sobre la situación de la tuberculosis en España. Año 2022. Centro Nacional de Epidemiología. Instituto de Salud Carlos III [Internet] [accessed Nov 2024]. Available from: – year: 2019 [accessed Nov 2024] ident: bib0190 article-title: Plan para la Prevención y Control de la Tuberculosis en España – year: 2023 [accessed Nov 2024] ident: bib0260 article-title: World Health Organization standard: universal access to rapid tuberculosis diagnostics – reference: [revised March 2024]. – volume: 273 start-page: 220 year: 1995 end-page: 226 [accessed Nov 2024] ident: bib0150 article-title: Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic publication-title: JAMA – reference: Red Nacional de Vigilancia Epidemiológica (RENAVE). Informe epidemiológico sobre la situación de la tuberculosis en España. Años del 2015 al 2021. Centro Nacional de Epidemiología. Instituto de Salud Carlos III [Internet] [accessed Nov 2024]. Available from: – volume: 24 start-page: 698 year: 2024 end-page: 725 [accessed Nov 2024] ident: bib0235 article-title: Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 publication-title: Lancet Infect Dis – volume: 26 start-page: 2709 year: 2020 end-page: 2712 ident: bib0205 article-title: Worldwide effects of coronavirus disease pandemic on tuberculosis services, January–April 2020 publication-title: Emerg Infect Dis – volume: 114 start-page: 530 year: 2000 end-page: 537 [accessed Nov 2024] ident: bib0180 article-title: Incidencia de la tuberculosis en España: resultados del Proyecto Multicéntrico de Investigación en Tuberculosis (PMIT) publication-title: Med Clin (Barc) – volume: 1 start-page: 91 year: 1997 end-page: 92 ident: bib0175 article-title: Pilot study for the Multicenter Project to Tuberculosis Research (MPTR) publication-title: Int J Tuberc Lung Dis – year: 2016 [accessed Nov 2024] ident: bib0170 article-title: Implementación de la estrategia fin de la TB: aspectos esenciales. Geneva – year: 2024 [accessed Nov 2024] ident: bib0215 article-title: Tuberculosis surveillance and monitoring in Europe 2024–2022 data – year: 1994 [accessed Nov 2024] ident: bib0145 article-title: TB: a global emergency. Geneva – volume: 22 start-page: S539 year: 2013 end-page: S548 ident: bib0245 article-title: Factors that influence current tuberculosis epidemiology publication-title: Eur Spine J – year: 2023 [accessed Nov 2024] ident: bib0155 article-title: Global tuberculosis report. Geneva – year: 2007 [accessed Nov 2024] ident: bib0185 article-title: Plan para la Prevención y Control de la Tuberculosis en España – volume: 113 start-page: 604 year: 1999 [accessed Nov 2024] end-page: 607 ident: bib0225 article-title: Evaluación de los programas de control de tuberculosis de las Comunidades Autónomas de España publication-title: Med Clin (Barc) – year: 2022 [accessed Nov 2024] ident: bib0240 article-title: Implementing the End TB Strategy: the essentials. 2022 update. Geneva – year: 2023 [accessed Nov 2024] ident: bib0220 article-title: Tuberculosis action plan for the World Health Organization European Region, 2023–2030 – volume: 59 start-page: 714 year: 2023 end-page: 716 ident: bib0230 article-title: Tuberculosis elimination: myth or achievable target? publication-title: Arch Bronconeumol – year: 2024 [accessed Nov 2024] ident: bib0280 article-title: Evaluación intermedia del plan para la prevención y control de la tuberculosis en España 2019-2030 [Internet]. Madrid – volume: 375 start-page: 1814 year: 2010 end-page: 1829 [accessed Nov 2024] ident: bib0265 article-title: Tuberculosis control and elimination 2010–50: cure, care, and social development publication-title: Lancet – year: 2024 [accessed Nov 2024] ident: bib0270 article-title: Guidance on social protection for people affected by tuberculosis. Geneva – volume: 27 start-page: 681 year: 2021 end-page: 686 ident: bib0195 article-title: Parallels and mutual lessons in tuberculosis and COVID-19 transmission, prevention, and control publication-title: Emerg Infect Dis – year: 2015 [accessed Nov 2024] ident: bib0165 article-title: End TB Strategy. Geneva – year: 2020 [accessed Nov 2024] ident: bib0200 article-title: Pulse survey on continuity of essential health services during the Covid-19 pandemic – volume: 70 start-page: 149 year: 1992 end-page: 159 [accessed Nov 2024] ident: bib0160 article-title: Tuberculosis: an overview of the current situation publication-title: Bull World Health Organisation – volume: 29 start-page: 2 year: 2011 end-page: 7 [accessed Nov 2024] ident: bib0275 article-title: Present epidemiology of tuberculosis. Prevention and control programs publication-title: Enferm Infecc Microbiol Clin – reference: [revised April 2024]. – year: 2021 [accessed Nov 2024] ident: bib0255 article-title: Information Note. COVID-19: considerations for tuberculosis (TB) care – year: 1994 ident: 10.1016/j.eimce.2025.02.017_bib0145 – year: 2021 ident: 10.1016/j.eimce.2025.02.017_bib0255 – volume: 22 start-page: S539 issue: Suppl. 4 year: 2013 ident: 10.1016/j.eimce.2025.02.017_bib0245 article-title: Factors that influence current tuberculosis epidemiology publication-title: Eur Spine J doi: 10.1007/s00586-012-2334-8 – volume: 375 start-page: 1814 year: 2010 ident: 10.1016/j.eimce.2025.02.017_bib0265 article-title: Tuberculosis control and elimination 2010–50: cure, care, and social development publication-title: Lancet doi: 10.1016/S0140-6736(10)60483-7 – year: 2023 ident: 10.1016/j.eimce.2025.02.017_bib0220 – volume: 24 start-page: 698 year: 2024 ident: 10.1016/j.eimce.2025.02.017_bib0235 article-title: Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(24)00007-0 – volume: 27 start-page: 681 year: 2021 ident: 10.1016/j.eimce.2025.02.017_bib0195 article-title: Parallels and mutual lessons in tuberculosis and COVID-19 transmission, prevention, and control publication-title: Emerg Infect Dis doi: 10.3201/eid2703.203456 – volume: 1 start-page: 91 issue: Suppl. 1 year: 1997 ident: 10.1016/j.eimce.2025.02.017_bib0175 article-title: Pilot study for the Multicenter Project to Tuberculosis Research (MPTR) publication-title: Int J Tuberc Lung Dis – year: 2020 ident: 10.1016/j.eimce.2025.02.017_bib0200 – year: 2023 ident: 10.1016/j.eimce.2025.02.017_bib0155 – volume: 59 start-page: 714 year: 2023 ident: 10.1016/j.eimce.2025.02.017_bib0230 article-title: Tuberculosis elimination: myth or achievable target? publication-title: Arch Bronconeumol doi: 10.1016/j.arbres.2023.09.002 – ident: 10.1016/j.eimce.2025.02.017_bib0250 – volume: 29 start-page: 2 issue: Suppl. 1 year: 2011 ident: 10.1016/j.eimce.2025.02.017_bib0275 article-title: Present epidemiology of tuberculosis. Prevention and control programs publication-title: Enferm Infecc Microbiol Clin doi: 10.1016/S0213-005X(11)70011-8 – volume: 114 start-page: 530 year: 2000 ident: 10.1016/j.eimce.2025.02.017_bib0180 article-title: Incidencia de la tuberculosis en España: resultados del Proyecto Multicéntrico de Investigación en Tuberculosis (PMIT) publication-title: Med Clin (Barc) doi: 10.1016/S0025-7753(00)71354-6 – ident: 10.1016/j.eimce.2025.02.017_bib0210 – year: 2024 ident: 10.1016/j.eimce.2025.02.017_bib0280 – year: 2024 ident: 10.1016/j.eimce.2025.02.017_bib0215 – year: 2015 ident: 10.1016/j.eimce.2025.02.017_bib0165 – volume: 70 start-page: 149 year: 1992 ident: 10.1016/j.eimce.2025.02.017_bib0160 article-title: Tuberculosis: an overview of the current situation publication-title: Bull World Health Organisation – volume: 26 start-page: 2709 year: 2020 ident: 10.1016/j.eimce.2025.02.017_bib0205 article-title: Worldwide effects of coronavirus disease pandemic on tuberculosis services, January–April 2020 publication-title: Emerg Infect Dis doi: 10.3201/eid2611.203163 – year: 2019 ident: 10.1016/j.eimce.2025.02.017_bib0190 – volume: 113 start-page: 604 year: 1999 ident: 10.1016/j.eimce.2025.02.017_bib0225 article-title: Evaluación de los programas de control de tuberculosis de las Comunidades Autónomas de España publication-title: Med Clin (Barc) – year: 2024 ident: 10.1016/j.eimce.2025.02.017_bib0270 – year: 2007 ident: 10.1016/j.eimce.2025.02.017_bib0185 – year: 2022 ident: 10.1016/j.eimce.2025.02.017_bib0240 – year: 2016 ident: 10.1016/j.eimce.2025.02.017_bib0170 – volume: 273 start-page: 220 year: 1995 ident: 10.1016/j.eimce.2025.02.017_bib0150 article-title: Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic publication-title: JAMA doi: 10.1001/jama.1995.03520270054031 – year: 2023 ident: 10.1016/j.eimce.2025.02.017_bib0260 |
| SSID | ssj0002961534 |
| Score | 2.2993684 |
| Snippet | End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 426 |
| SubjectTerms | Control programmes COVID-19 COVID-19 - epidemiology Eliminación Elimination Europe - epidemiology Evaluación Evaluation Forecasting Humans Incidence Incidencia Longitudinal Studies Pandemics Programas de control Retrospective Studies Spain - epidemiology Tuberculosis - epidemiology Tuberculosis - prevention & control |
| Title | Evolution of tuberculosis in Spain: Will the objectives of the End TB Strategy be achieved in Western European countries? |
| URI | https://dx.doi.org/10.1016/j.eimce.2025.02.017 https://www.ncbi.nlm.nih.gov/pubmed/40467409 https://www.proquest.com/docview/3215985023 |
| Volume | 43 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 2529-993X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002961534 issn: 2529-993X databaseCode: AIEXJ dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9NAFB514cAFgdjCUg0SN-PIHu9cUIOCAJUK0VTkZtkz4-IotaO4iZrfzoU3a6yWVoDExbJGtsea9_ltfu8bhF4nYGY8RjKXBgQCFIiB3CKihZsGaZIRmoGNkuz6R8nxcTqdZl93dn6aXpj1PGma9PIyW_xXUcMYCFu0zv6FuO1DYQDOQehwBLHD8Y8EP17rx8vf_6uSL-lq3grekRo-5YXIBARSG8yl09mWM6XzOlMuMG6YMxk5mrd240jGjR81X3PB0-R8V9wKjs3jy-0mRMR9tUhQ9BKCsS2YKfqiddsVnbNxzmvL_1Tb7kzh7OquYoezYS9H8a1ly_pMJnUnfMk7a0pkJ6P6m9IKbT7slQisW92LpCrNVHoCVqPhqrUHYgjny7Cf9SCRrbnTqTjTjjMGvStKCka-9LVPhkfD060KJRGgEDywqbJ2vxnTNkBRRWmsJz2FHpK45xuEKvF6zeyoDMgMZjingnuVRJIIVnWlXuHzPhEvIOYH51MQ5oW7aJ8kUQYqef_w03j62aYISSa8cVEXYd_Z8GbJCsVrs93kW90UO0kfanIf3dPBDz5UoH2AdnjzEG0sYHFb4T5gcd1gCdi3WMAVAzjxFq7yahgBuOLJCBu44pJjA1fxAA1XbOCKLVzfPUKnH8aT9x9dvSGISwlEsm4QZQUhRclij1a84hGpSt-Py5JzcMa8ABytLExIWPklK4MirUoCS-V5jBY0YnEVPEZ7TdvwpwhXzKuChIkKhiSMI78MaFHRNPZC5vMoYQNEzFLmVLPli01b5rkpi5zlcv1zsf65R3JY_wF6Y29aKLKY2y-PjYxy7e8qPzYHXN1-4ysj0RysgfjFVzS8XXU5KNwoSyNwxAfoiRK1fZPQEzsLedmzf532Obq7_RRfoL2L5Yq_RHfo-qLulgdoN5mmBxrDvwAMmOVV |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evolution+of+tuberculosis+in+Spain%3A+Will+the+objectives+of+the+End+TB+Strategy+be+achieved+in+Western+European+countries%3F&rft.jtitle=Enfermedades+infecciosas+y+microbiologia+clinica+%28English+ed.%29&rft.au=Rodrigo%2C+Teresa&rft.au=Millet%2C+Joan+P.&rft.au=Bravo%2C+Mario&rft.au=Tabernero%2C+Eva+M.&rft.date=2025-08-01&rft.pub=Elsevier+Espa%C3%B1a%2C+S.L.U&rft.issn=2529-993X&rft.eissn=2529-993X&rft.volume=43&rft.issue=7&rft.spage=426&rft.epage=434&rft_id=info:doi/10.1016%2Fj.eimce.2025.02.017&rft.externalDocID=S2529993X25001364 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2529-993X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2529-993X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2529-993X&client=summon |